Compare Inovio Pharmaceuticals Inc (INO) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Schlumberger NV — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Schlumberger NV trades at $46.55 (market cap $69.36B). The key difference: Schlumberger NV is far larger — about 777× Inovio Pharmaceuticals Inc's market cap, and Schlumberger NV pays a 2.54% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | SLB | |
|---|---|---|
Market Cap | $89.27M | $69.36B |
Sector | Health | Energy |
52-Week High | $2.87 | $58.01 |
52-Week Low | $1.05 | $31.72 |
Enterprise Value | $60.28M | $77.58B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
SLB trades at $46.67, down 0.68% on the day, with a bearish technical signal from moving averages. The company reported revenue of $35.71 billion in 2025 with a net income margin of 9.26%, and has beaten EPS estimates in three consecutive quarters. Recent news highlights strategic alliances for data center power solutions and new contract wins, signaling growth in digital and offshore segments.
The outlook is supported by strong analyst consensus with a $62.83 price target and 84.85% buy ratings, but risks include oil price volatility and execution challenges. The stock offers value with a P/E of 20.7 and ROE of 14.57%, though margin compression from 2024 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
